Camber Spine delves into biologics with portfolio expansion

Written by Alan Condon | August 07, 2019 | Print  |

Camber Spine is widening its portfolio by tapping into the biologics market.

Four insights:

1. The company signed a private label agreement with a biologics company to enter the cellular bone graft market.

2. Camber Spine's allogenic bone matrix product, Scylla, consists of spine-derived cells to support the osteogenic healing process.

3. Scylla features an osteoconductive 3D scaffold with cortical and cancellous properties and demineralized bone scaffold with osteoinductive potential.

4. Zion Market Research reported the global bone grafts and substitutes market to be a $2.7 billion industry, predicted to grow to $4.2 billion by 2026.

More articles on biologics:
Dr. Robert Brady: Robotics in spinal fusion and how the trend will develop in spine
Orthofix names DePuy, Medtronic, Biomet veteran the next CEO
Medicrea receives FDA approval for new screw device




© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months